[Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence].
作者信息
Salinas-Botrán A, Pérez-Belmonte L M, Méndez-Bailón M
机构信息
Servicio de Medicina Interna, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, España.
Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Málaga, España.
出版信息
Rev Clin Esp. 2022 May;222(5):310-311. doi: 10.1016/j.rce.2021.11.001. Epub 2021 Nov 20.
Abstract
摘要
相似文献
1
[Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence].[对“COVID-19合并心力衰竭患者的糖皮质激素治疗”信件的回复]
Rev Clin Esp. 2022 May;222(5):310-311. doi: 10.1016/j.rce.2021.11.001. Epub 2021 Nov 20.
2
Answer to the "Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure" correspondence.对“COVID-19合并心力衰竭患者的糖皮质激素治疗”信件的回复。
Rev Clin Esp (Barc). 2022 May;222(5):310-311. doi: 10.1016/j.rceng.2021.11.001. Epub 2022 Jan 24.
3
Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure.新冠病毒病合并心力衰竭患者的糖皮质激素治疗
Rev Clin Esp (Barc). 2022 May;222(5):309-310. doi: 10.1016/j.rceng.2021.11.002. Epub 2022 Jan 31.
4
[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure].[新型冠状病毒肺炎合并心力衰竭患者的糖皮质激素治疗]
Rev Clin Esp. 2022 May;222(5):309-310. doi: 10.1016/j.rce.2021.11.002. Epub 2021 Nov 20.
5
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo .风湿性疾病活动、糖皮质激素使用与2019冠状病毒病。对以下内容的回应：“关于‘风湿性疾病患者2019冠状病毒病住院相关特征：来自2019冠状病毒病全球风湿病联盟医生报告登记处的数据’的通信”，作者为詹弗兰切斯科。乔洛指出：“在风湿性肌肉骨骼疾病患者中，疾病活动而非糖皮质激素治疗可能与2019冠状病毒病的严重程度相关。”
Ann Rheum Dis. 2022 Nov;81(11):e223. doi: 10.1136/annrheumdis-2020-218910. Epub 2020 Sep 7.
6
Association between glucocorticoid use and all-cause mortality in critically ill patients with heart failure: A cohort study based on the MIMIC-III database.糖皮质激素使用与重症心力衰竭患者全因死亡率之间的关联：一项基于MIMIC-III数据库的队列研究。
Front Pharmacol. 2023 Jan 12;14:1118551. doi: 10.3389/fphar.2023.1118551. eCollection 2023.
7
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases.关于吉安弗兰切斯科所著《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在风湿性肌肉骨骼疾病患者中，疾病活动度而非糖皮质激素治疗，可能与新冠病毒肺炎的严重程度相关。
Ann Rheum Dis. 2022 Nov;81(11):e222. doi: 10.1136/annrheumdis-2020-218845. Epub 2020 Sep 7.
8
[Clinical effect of Shenfu injection combined with glucocorticoid on patients with acute left heart failure complicated with bronchospasm].参附注射液联合糖皮质激素治疗急性左心衰竭合并支气管痉挛患者的临床疗效
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Dec;35(12):1298-1303. doi: 10.3760/cma.j.cn121430-20230726-00557.
9
Response to: 'Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'' by Jeny .对珍妮的《关于“结节病患者糖皮质激素诱导的COVID-19复发”的通信》的回复 。
Ann Rheum Dis. 2022 Dec;81(12):e242. doi: 10.1136/annrheumdis-2020-218983. Epub 2020 Oct 1.
10
Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience.糖皮质激素治疗 COVID-19 肺炎患者的临床疗效：一项单中心经验。
Biomed Pharmacother. 2020 Oct;130:110529. doi: 10.1016/j.biopha.2020.110529. Epub 2020 Jul 28.
本文引用的文献
1
[Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure].[新型冠状病毒肺炎合并心力衰竭患者的糖皮质激素治疗]
Rev Clin Esp. 2022 May;222(5):309-310. doi: 10.1016/j.rce.2021.11.002. Epub 2021 Nov 20.
2
Adverse outcomes in patients with heart failure admitted for COVID‑19 in association with the use of renin-angiotensin‑aldosterone system inhibitors.
Pol Arch Intern Med. 2022 Jan 28;132(1). doi: 10.20452/pamw.16126. Epub 2021 Oct 22.
3
Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study.因COVID-19住院的心力衰竭患者的皮质类固醇治疗：一项多中心回顾性研究。
Intern Emerg Med. 2021 Nov;16(8):2301-2305. doi: 10.1007/s11739-021-02843-4. Epub 2021 Oct 12.
4
[Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain].[西班牙因COVID-19住院的心力衰竭患者入院时的临床特征及死亡风险因素]
Rev Clin Esp. 2022 May;222(5):255-265. doi: 10.1016/j.rce.2021.06.004. Epub 2021 Jul 17.
5
[Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry].[西班牙新冠肺炎住院患者的临床特征：SEMI-COVID-19登记研究结果]
Rev Clin Esp. 2020 Nov;220(8):480-494. doi: 10.1016/j.rce.2020.07.003. Epub 2020 Jul 19.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
Zotero 插件